NYSE · Healthcare · Drug Manufacturers - General
Latest call day: 2026-10-23 · full consensus board · graded history
Price (daily close, 2026-10-23)
Trailing returns (daily closes)
Today's calls AI
| Pharma & Managed Care · OBV Trend | UP 100% | OBV Trend — on-balance-volume accumulation. ABBV ranks #1 of 13 in Pharma & Managed Care (100% bullish percentile), so the agent calls it UP for the next session. |
| Pharma & Managed Care · Mean-Reversion | UP 75% | Mean-Reversion — contrarian on the trailing return. ABBV ranks #4 of 13 in Pharma & Managed Care (75% bullish percentile, recent move +0.6%, fading it), so the agent calls it UP for the next session. |
| Pharma & Managed Care · Quality | UP 75% | Quality — operating margin plus revenue growth. ABBV ranks #4 of 13 in Pharma & Managed Care (75% bullish percentile), so the agent calls it UP for the next session. |
| Pharma & Managed Care · Long-Term Reversal | UP 50% | Long-Term Reversal — year-long losers rebound. ABBV ranks #7 of 13 in Pharma & Managed Care (50% bullish percentile, signal -26.9%), so the agent calls it UP for the next session. |
Best agents on ABBV (graded record)
| Pharma & Managed Care · Meta-Ensemble | 69% | 9/13 correct | UP |
| 3-Month Momentum | 60% | 3/5 correct | UP |
| Pharma & Managed Care · Breakout | 60% | 28/47 correct | DOWN |
| Pharma & Managed Care · Quality | 58% | 31/53 correct | UP |
| Pharma & Managed Care · RSI Mean-Reversion | 57% | 30/53 correct | DOWN |
| Pharma & Managed Care · Momentum Acceleration | 56% | 9/16 correct | DOWN |
| Pharma & Managed Care · Long-Term Reversal | 54% | 39/72 correct | UP |
| Pharma & Managed Care · MACD | 54% | 27/50 correct | UP |
| Pharma & Managed Care · OBV Trend | 54% | 29/54 correct | UP |
| Pharma & Managed Care · Trend Strength | 53% | 16/30 correct | UP |
Recent news
| 2026-10-24 | AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases · yf_tkr_ABBV |
| 2026-10-23 | FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi · investing_com |
| 2026-10-23 | U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease · pr_newswire_finance |
| 2026-10-23 | AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? · yf_tkr_ABBV |
| 2026-10-23 | BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? · yf_tkr_ABBV |
| 2026-10-23 | Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market · yf_tkr_ABBV |
How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.
Open Fortivio.AI →Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。